Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring RET fusion: a case report

Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring RET fusion: a case report

Neoadjuvant chemoimmunotherapy has demonstrated significant benefit for resectable non-small-cell lung cancer (NSCLC) excluding known EGFR/ALK genetic alterations. Recent evidence has shown that neoadjuvant chemoimmunotherapy could be clinically valuable in resectable localized driver gene-mutant NS...

Full description

Bibliographic Details
Main Authors: Minqian Dai, Na Wang, Qin Xia, Yongde Liao, Wei Cao, Jun Fan, Diwei Zhou, Sihua Wang, Xiu Nie
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
lung adenocarcinoma
stage IIIA
RET fusion
neoadjuvant chemoimmunotherapy
pathological complete response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1258762/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1258762/full

Similar Items